Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 25, 2013. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,520,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,614.50 pence per share; lowest price paid was 1,588.50 pence per share.
- Treasury Holdings (Settled): 475,204,412 shares (8.86% of total issued share capital).
- Treasury Holdings (Including Unsettled): 479,674,412 shares (9.81% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,889,996,277 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,520,000 shares on September 25, 2013. Consequently, the percentage of shares held in Treasury increased to 8.86% of issued capital and 9.81% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Conduct Authority's Disclosure and Transparency Rules regarding share repurchases.
Investor Verification Points
- Verify the total number of shares in issue (4,889,996,277) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (475,204,412 settled) for assessing dilution or buyback program progress.
- Note that the filing does not include operational or financial performance metrics for the period.